S&P 500   3,611.02 (-0.75%)
DOW   29,562.88 (-1.16%)
QQQ   297.60 (-0.47%)
AAPL   118.86 (+1.95%)
MSFT   212.31 (-1.36%)
FB   274.39 (-1.23%)
GOOGL   1,753.91 (-1.85%)
AMZN   3,139.43 (-1.75%)
TSLA   580.49 (-0.90%)
NVDA   526.20 (-0.80%)
BABA   265.15 (-4.10%)
CGC   28.67 (-1.14%)
GE   10.26 (-1.35%)
MU   64.59 (+0.56%)
AMD   91.02 (+4.39%)
T   28.92 (-0.38%)
NIO   51.47 (-4.69%)
F   9.09 (+0.00%)
ACB   11.07 (+5.73%)
NFLX   485.40 (-1.21%)
BA   213.47 (-1.40%)
GILD   60.04 (+0.02%)
DIS   147.29 (+0.11%)
S&P 500   3,611.02 (-0.75%)
DOW   29,562.88 (-1.16%)
QQQ   297.60 (-0.47%)
AAPL   118.86 (+1.95%)
MSFT   212.31 (-1.36%)
FB   274.39 (-1.23%)
GOOGL   1,753.91 (-1.85%)
AMZN   3,139.43 (-1.75%)
TSLA   580.49 (-0.90%)
NVDA   526.20 (-0.80%)
BABA   265.15 (-4.10%)
CGC   28.67 (-1.14%)
GE   10.26 (-1.35%)
MU   64.59 (+0.56%)
AMD   91.02 (+4.39%)
T   28.92 (-0.38%)
NIO   51.47 (-4.69%)
F   9.09 (+0.00%)
ACB   11.07 (+5.73%)
NFLX   485.40 (-1.21%)
BA   213.47 (-1.40%)
GILD   60.04 (+0.02%)
DIS   147.29 (+0.11%)
S&P 500   3,611.02 (-0.75%)
DOW   29,562.88 (-1.16%)
QQQ   297.60 (-0.47%)
AAPL   118.86 (+1.95%)
MSFT   212.31 (-1.36%)
FB   274.39 (-1.23%)
GOOGL   1,753.91 (-1.85%)
AMZN   3,139.43 (-1.75%)
TSLA   580.49 (-0.90%)
NVDA   526.20 (-0.80%)
BABA   265.15 (-4.10%)
CGC   28.67 (-1.14%)
GE   10.26 (-1.35%)
MU   64.59 (+0.56%)
AMD   91.02 (+4.39%)
T   28.92 (-0.38%)
NIO   51.47 (-4.69%)
F   9.09 (+0.00%)
ACB   11.07 (+5.73%)
NFLX   485.40 (-1.21%)
BA   213.47 (-1.40%)
GILD   60.04 (+0.02%)
DIS   147.29 (+0.11%)
S&P 500   3,611.02 (-0.75%)
DOW   29,562.88 (-1.16%)
QQQ   297.60 (-0.47%)
AAPL   118.86 (+1.95%)
MSFT   212.31 (-1.36%)
FB   274.39 (-1.23%)
GOOGL   1,753.91 (-1.85%)
AMZN   3,139.43 (-1.75%)
TSLA   580.49 (-0.90%)
NVDA   526.20 (-0.80%)
BABA   265.15 (-4.10%)
CGC   28.67 (-1.14%)
GE   10.26 (-1.35%)
MU   64.59 (+0.56%)
AMD   91.02 (+4.39%)
T   28.92 (-0.38%)
NIO   51.47 (-4.69%)
F   9.09 (+0.00%)
ACB   11.07 (+5.73%)
NFLX   485.40 (-1.21%)
BA   213.47 (-1.40%)
GILD   60.04 (+0.02%)
DIS   147.29 (+0.11%)
Log in
NASDAQ:MASI

Masimo Stock Forecast, Price & News

$253.22
-1.19 (-0.47 %)
(As of 11/30/2020 12:26 PM ET)
Add
Compare
Today's Range
$248.60
Now: $253.22
$255.22
50-Day Range
$223.82
MA: $241.18
$254.94
52-Week Range
$143.90
Now: $253.22
$259.29
Volume7,547 shs
Average Volume493,206 shs
Market Capitalization$13.94 billion
P/E Ratio65.77
Dividend YieldN/A
Beta0.85
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software for Masimo Root and Radical-7 monitors. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, home care providers, long term care facilities, veterinarians, and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Read More
Masimo logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000
Employees1,600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$937.84 million
Cash Flow$4.03 per share
Book Value$25.70 per share

Profitability

Net Income$196.22 million

Miscellaneous

Market Cap$13.94 billion
Next Earnings Date2/17/2021 (Estimated)
OptionableOptionable
$253.22
-1.19 (-0.47 %)
(As of 11/30/2020 12:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Masimo (NASDAQ:MASI) Frequently Asked Questions

How has Masimo's stock been impacted by Coronavirus?

Masimo's stock was trading at $182.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MASI shares have increased by 37.9% and is now trading at $251.77.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Masimo?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Masimo
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Masimo?

Wall Street analysts have given Masimo a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Masimo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for Masimo
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) announced its earnings results on Saturday, October, 31st. The medical equipment provider reported $0.80 EPS for the quarter, topping the Zacks' consensus estimate of $0.62 by $0.18. The medical equipment provider earned $278.11 million during the quarter, compared to analysts' expectations of $275 million. Masimo had a net margin of 20.30% and a return on equity of 15.75%.
View Masimo's earnings history
.

What guidance has Masimo issued on next quarter's earnings?

Masimo issued an update on its fourth quarter earnings guidance on Tuesday, October, 27th. The company provided EPS guidance of $0.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.74. The company issued revenue guidance of $279.3 million, compared to the consensus revenue estimate of $266.22 million.

What price target have analysts set for MASI?

8 equities research analysts have issued 1-year price targets for Masimo's stock. Their forecasts range from $175.00 to $280.00. On average, they expect Masimo's share price to reach $244.57 in the next year. This suggests that the stock has a possible downside of 2.9%.
View analysts' price targets for Masimo
.

Who are some of Masimo's key competitors?

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), The Trade Desk (TTD), The Walt Disney (DIS) and Twilio (TWLO).

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 55, Pay $3M)
  • Mr. Micah Young, Exec. VP of Fin. & CFO (Age 41, Pay $713.37k)
  • Mr. Bilal Muhsin, Chief Operating Officer (Age 39, Pay $892.51k)
  • Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 75, Pay $190k)
  • Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $718.05k)
  • Mr. Anand Sampath, Exec. VP of Operations & Clinical Research (Age 54, Pay $774.84k)
  • Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 55)
  • Mr. Eli Kammerman, VP of Bus. Devel. & Investor Relations
  • Mr. Jon Coleman, Pres of Worldwide Sales, Professional Services & Medical Affairs (Age 56)
  • Mr. Thierry Leclercq, Exec. VP of Bus. Devel. (Age 64)

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.35%), State Street Corp (2.99%), Massachusetts Financial Services Co. MA (1.88%), Victory Capital Management Inc. (1.40%), Champlain Investment Partners LLC (1.32%) and Neuberger Berman Group LLC (1.30%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo
.

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., BNP Paribas Arbitrage SA, AQR Capital Management LLC, First Trust Advisors LP, Federated Hermes Inc., and Virginia Retirement Systems ET AL. Company insiders that have sold Masimo company stock in the last year include Adam Mikkelson, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan, and Yongsam Lee.
View insider buying and selling activity for Masimo
.

Which major investors are buying Masimo stock?

MASI stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., California Public Employees Retirement System, BNP PARIBAS ASSET MANAGEMENT Holding S.A., Great West Life Assurance Co. Can, Neuberger Berman Group LLC, Vaughan Nelson Investment Management L.P., Parian Global Management LP, and Ensemble Capital Management LLC.
View insider buying and selling activity for Masimo
.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $251.77.

How big of a company is Masimo?

Masimo has a market capitalization of $13.86 billion and generates $937.84 million in revenue each year. The medical equipment provider earns $196.22 million in net income (profit) each year or $3.22 on an earnings per share basis. Masimo employs 1,600 workers across the globe.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.